Enlivex (ENLV) Retained Earnings (2013 - 2025)
Enlivex (ENLV) posted quarterly Retained Earnings of $1.1 billion for Q4 2025, up 654.49% year-over-year from $146.9 million in Q4 2024, and up 923.3% quarter-over-quarter from -$134.6 million in Q3 2025.
Enlivex (ENLV) Retained Earnings (2013 - 2025) Analysis & Trends
Enlivex's Retained Earnings history runs 13 years deep, the most recent figure standing at $1.1 billion for Q4 2025.
- In Q4 2025, Retained Earnings rose 654.49% year-over-year to $1.1 billion; the TTM figure through Dec 2025 stood at $1.1 billion (up 654.49% YoY), while the FY2025 annual figure was $1.1 billion, up 654.49% from the prior year.
- Retained Earnings for Q4 2025 stood at $1.1 billion, up from -$134.6 million in the prior quarter.
- The five-year high for Retained Earnings was $1.1 billion in Q4 2025, with the low at -$134.6 million in Q3 2025.
- The 5-year median for Retained Earnings is -$73.0 million (2022), against an average of $14.1 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings tumbled 60.57% in 2022, then jumped 654.49% in 2025.
- Enlivex's Retained Earnings stood at $133.8 million in 2021, then rose by 2.13% to $136.6 million in 2022, then gained by 1.68% to $138.9 million in 2023, then climbed by 5.74% to $146.9 million in 2024, then surged by 654.49% to $1.1 billion in 2025.
- Business Quant data shows ENLV's Retained Earnings at $1.1 billion in Q4 2025, -$134.6 million in Q3 2025, and -$132.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 1.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.11 Bn |
| Sep 30, 2025 | -134.63 Mn |
| Jun 30, 2025 | -132.43 Mn |
| Mar 31, 2025 | -130.56 Mn |
| Dec 31, 2024 | 146.91 Mn |
| Sep 30, 2024 | -121.93 Mn |
| Jun 30, 2024 | -119.33 Mn |
| Mar 31, 2024 | -116.23 Mn |
| Dec 31, 2023 | 138.94 Mn |
| Sep 30, 2023 | -103.00 Mn |
| Jun 30, 2023 | -97.04 Mn |
| Mar 31, 2023 | -90.24 Mn |
| Dec 31, 2022 | 136.65 Mn |
| Sep 30, 2022 | -75.84 Mn |
| Jun 30, 2022 | -70.10 Mn |
| Mar 31, 2022 | -60.19 Mn |
| Dec 31, 2021 | 133.80 Mn |
| Sep 30, 2021 | -47.23 Mn |
| Jun 30, 2021 | -43.81 Mn |
| Mar 31, 2021 | -40.70 Mn |